Skip to content
Wenlo
Sign in
← Markets

Enliven Therapeutics, Inc.

Benjamin Hohl (CHIEF FINANCIAL OFFICER) sells ELVN shares

4ELVNFiled Oct 21, 2026, 1:53 PM ET· Period Oct 19, 2026

About this filing

Enliven Therapeutics, Inc. (ELVN) filed Form 4 (insider transaction) with the SEC on Oct 21, 2026. Form 4 reports a company insider’s trades in the company’s shares.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Benjamin Hohl · CHIEF FINANCIAL OFFICER

Rule 10b5-1 plan · adopted Mar 18, 2026

DateTransactionSharesPriceValueHeld afterOwnership
Oct 19, 2026M · exercise or conversion of a derivativeFootnotes F1, F2+6,018$14.85$89,367.3044,018Direct
Oct 19, 2026S · open-market saleFootnotes F1, F3, F2−6,018$38.48$231,545.5638,000Direct
Oct 19, 2026M · exercise or conversion of a derivativeStock Option (right to buy)Footnotes F1, F4−6,018$0.00$0.00175,000Direct
Footnotes
  1. F1 The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
  2. F2 Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
  3. F3 This transaction was executed in multiple trades at prices ranging from $37.785 to $38.765. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  4. F4 The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter.

More ELVN filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.